Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer : A Phase 2 Study. Commentary

Saved in:
Bibliographic Details
Published inEuropean urology Vol. 54; no. 5; pp. 1089 - 1096
Main Authors DI LORENZO, Giuseppe, FIGG, William D, LABIANCA, Roberto, DE PLACIDO, Sabino, OUDARD, Stéphane, FOSSA, Sophie D, MIRONE, Vincenzo, AUTORINO, Riccardo, LONGO, Nicola, IMBIMBO, Ciro, PELDONA, Sisto, GIORDANO, Antonio, GIULIANO, Mario
Format Journal Article
LanguageEnglish
Published Oxford Elsevier 2008
Subjects
Biological and medical sciences
Gynecology. Andrology. Obstetrics
Male genital diseases
Medical sciences
Nephrology. Urinary tract diseases
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Antineoplastic agent
Nephrology
Treatment resistance
Urinary system disease
Prostate disease
Hormone therapy
Docetaxel
Monoclonal antibody
Malignant tumor
Urology
Bevacizumab
Immunomodulator
Chemotherapy
Treatment
Vascular endothelium growth factor
Hormone-refractory prostate cancer
Taxane derivatives
Phase II trial
Antiangiogenic agent
Antimitotic
Male genital diseases
Prostate cancer
Cancer
Online AccessGet full text

Cover

More Information
ISSN:0302-2838
1873-7560